{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:08:09Z","timestamp":1785146889404,"version":"3.55.0"},"reference-count":46,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Triple-negative breast cancer (TNBC) lacking androgen receptor (AR) expression defines quadruple-negative breast cancer (QNBC), which is characterized by younger age at diagnosis, high Ki-67 index, and high genomic instability, however a comprehensive description of the genomic characteristics remains poorly defined. A total of 54 TNBC cases were categorized as TNBC with 100% AR expression (TNBC AR-100%) or QNBC, TNBC with 0% AR expression (TNBC AR-0%). Clinical, molecular, and genomic parameters, specifically pathogenic\/likely pathogenic (P\/LP) variants in homologous recombination repair (HRR) and cancer-related pathways were measured and analyzed. The QNBC cohort exhibited a high homologous recombination deficiency (HRD) score and a greater overall incidence of copy number variants (CNVs). QNBC harbored a higher mutation rate in TP53 and MYC signaling pathway than TNBC AR-100% tumors. P\/LP variants corresponding to the HRR, PI3K\/AKT, and RTK\/RAS pathways were exclusively identified in QNBC. These results suggest that, at both molecular and genomic levels, the two groups are distinct, holding QNBC tumors more aggressive characteristics, genomic instability, and particular impairments in HRR and cancer-related pathways. In terms of actionability, these differences could potentially be leveraged through different combinations of therapies.<\/jats:p>","DOI":"10.3390\/ijms27156654","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:47:41Z","timestamp":1785145661000},"page":"6654","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genomic Alterations in Quadruple-Negative Breast Cancer Tumors"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0928-9900","authenticated-orcid":false,"given":"Carolina","family":"Jaliffa","sequence":"first","affiliation":[{"name":"Institute of Pathology, Kantonsspital Baden AG, Im Ergel 1, 5404 Baden, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Rogel","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Kantonsspital Baden AG, Im Ergel 1, 5404 Baden, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1601-0281","authenticated-orcid":false,"given":"Cornelia","family":"Leo","sequence":"additional","affiliation":[{"name":"Breast Center, Kantonsspital Baden AG, Im Ergel 1, 5404 Baden, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8090-7267","authenticated-orcid":false,"given":"Gad","family":"Singer","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Kantonsspital Baden AG, Im Ergel 1, 5404 Baden, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12672-015-0232-3","article-title":"Androgen Receptor Biology in Triple Negative Breast Cancer: A Case for Classification as AR+ or Quadruple Negative Disease","volume":"6","author":"Barton","year":"2015","journal-title":"Horm. Cancer"},{"key":"ref_2","first-page":"1864","article-title":"Breast cancer molecular subtypes: From TNBC to QNBC","volume":"6","author":"Hon","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s12282-020-01047-6","article-title":"Quadruple negative breast cancer","volume":"27","author":"Huang","year":"2020","journal-title":"Breast Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13058-020-01369-5","article-title":"Quadruple-negative breast cancer: Novel implications for a new disease","volume":"22","author":"Bhattarai","year":"2020","journal-title":"Breast Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"You, C.P., Leung, M.H., Tsang, W.C., Khoo, U.S., and Tsoi, H. (2022). Androgen Receptor as an Emerging Feasible Biomarker for Breast Cancer. Biomolecules, 12.","DOI":"10.3390\/biom12010072"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e481154","DOI":"10.1200\/EDBK-25-481154","article-title":"New Treatment Approaches for Triple-Negative Breast Cancer","volume":"45","author":"Riaz","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s12672-025-03431-0","article-title":"Advances of androgen receptor in triple-negative breast cancer: From molecular mechanisms to clinical applications","volume":"16","author":"Ma","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s11596-025-00094-4","article-title":"Current Status and Advances in Anti-Androgen Therapy for Triple-Negative Breast Cancer","volume":"45","author":"Li","year":"2025","journal-title":"Curr. Med. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Bhattarai, S., Sugita, B.M., Bortoletto, S.M., Fonseca, A.S., Cavalli, L.R., and Aneja, R. (2021). QNBC Is Associated with High Genomic Instability Characterized by Copy Number Alterations and miRNA Deregulation. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111548"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.31557\/APJCP.2020.21.2.563","article-title":"Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response","volume":"21","author":"Mohammed","year":"2020","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.3332\/ecancer.2022.1452","article-title":"Clinicopathological features and androgen receptor expression in triple negative breast cancer at Lagos, Nigeria","volume":"16","author":"Haruna","year":"2022","journal-title":"ecancermedicalscience"},{"key":"ref_12","first-page":"359","article-title":"Androgen Receptor Status in Triple Negative Breast Cancer: Does It Correlate with Clinicopathological Characteristics?","volume":"15","author":"Dubrava","year":"2023","journal-title":"Breast Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"551","DOI":"10.4103\/jcrt.jcrt_461_24","article-title":"Androgen receptor expression in triple negative breast cancer: A report from a tertiary care center","volume":"21","author":"Dogra","year":"2025","journal-title":"J. Cancer Res. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Spurnic, I., Susnjar, S., Jovanic, I., Medic-Miljic, N., Milovanovic, Z., Popovic Krneta, M., Bukumiric, Z., Gavrilovic, D., Rajsic, S., and Markovic, I. (2025). The Diagnostics of Disease Relapse Within Five-Year Follow-Up and the Role of Androgen Receptor Expression in Patients with Early Triple-Negative Breast Cancer. Diagnostics, 15.","DOI":"10.3390\/diagnostics15060692"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Riaz, N., Idress, R., Habib, S., and Lalani, E.N. (2020). Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.01083"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"46482","DOI":"10.18632\/oncotarget.10208","article-title":"Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1016\/j.clbc.2020.01.002","article-title":"Prognostic Significance of Androgen Receptor Expression in Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis","volume":"20","author":"Xu","year":"2020","journal-title":"Clin. Breast Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.31557\/APJCP.2024.25.12.4115","article-title":"Effect of Androgen receptors in Triple-Negative Breast Cancer Given Neoadjuvant Therapy: A Systematic Review and Meta-Analysis","volume":"25","author":"Kalangi","year":"2024","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.annonc.2020.05.015","article-title":"Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo","volume":"31","author":"Karn","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Huang, X., Shao, D., Wu, H., Zhu, C., Guo, D., Zhou, Y., Chen, C., Lin, Y., Lu, T., and Zhao, B. (2020). Genomic Profiling Comparison of Germline BRCA and Non-BRCA Carriers Reveals CCNE1 Amplification as a Risk Factor for Non-BRCA Carriers in Patients With Triple-Negative Breast Cancer. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.583314"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"12386","DOI":"10.1038\/s41598-024-62991-3","article-title":"Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer","volume":"14","author":"Li","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s12282-019-01043-5","article-title":"Microsatellite instability in Japanese female patients with triple-negative breast cancer","volume":"27","author":"Kurata","year":"2020","journal-title":"Breast Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Wang, W., Zhou, R., Wu, Y., Liu, Y., Su, W., Xiong, W., and Zeng, Z. (2019). PVT1 Promotes Cancer Progression via MicroRNAs. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00609"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"11278","DOI":"10.1038\/s41598-024-61640-z","article-title":"Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification","volume":"14","author":"Lee","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-018-05120-9","article-title":"Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC","volume":"174","author":"Imanishi","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Network (2012). Comprehensive molecular portraits of human breast tumours. Nature, 490, 61\u201370.","DOI":"10.1038\/nature11412"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/annonc\/mdy024","article-title":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","volume":"29","author":"Bareche","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Tierno, D., Grassi, G., Scomersi, S., Bortul, M., Generali, D., Zanconati, F., and Scaggiante, B. (2023). Next-Generation Sequencing and Triple-Negative Breast Cancer: Insights and Applications. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119688"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-018-0850-9","article-title":"Therapeutic landscape in mutational triple negative breast cancer","volume":"17","author":"Shi","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.tranon.2018.11.008","article-title":"Quadruple Negative Breast Cancers (QNBC) Demonstrate Subtype Consistency among Primary and Recurrent or Metastatic Breast Cancer","volume":"12","author":"Angajala","year":"2019","journal-title":"Transl. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ccell.2024.03.006","article-title":"Genetic interactions reveal distinct biological and therapeutic implications in breast cancer","volume":"42","author":"Lin","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/annonc\/mdz036","article-title":"Genomic alterations in breast cancer: Level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"30","author":"Condorelli","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.19.00368","article-title":"Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial","volume":"38","author":"Schmid","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1158\/1078-0432.CCR-20-3089","article-title":"Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer","volume":"27","author":"Keenan","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ddtec.2016.06.004","article-title":"Clinical trials for BET inhibitors run ahead of the science","volume":"19","author":"Andrieu","year":"2016","journal-title":"Drug Discov. Today Technol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/2159-8290.CD-23-0467","article-title":"Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer","volume":"14","author":"Suehnholz","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: A Precision Oncology Knowledge Base","volume":"1","author":"Chakravarty","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"D980","DOI":"10.1093\/nar\/gkt1113","article-title":"ClinVar: Public archive of relationships among sequence variation and human phenotype","volume":"42","author":"Landrum","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic Signaling Pathways in The Cancer Genome Atlas","volume":"173","author":"Mina","year":"2018","journal-title":"Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrc3181","article-title":"BRCA1 and BRCA2: Different roles in a common pathway of genome protection","volume":"12","author":"Roy","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00286","article-title":"Prevalence of Homologous Recombination\u2013Related Gene Mutations Across Multiple Cancer Types","volume":"2","author":"Heeke","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Mekonnen, N., Yang, H., and Shin, Y.K. (2022). Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.880643"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","article-title":"Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal","volume":"83","author":"Kundra","year":"2023","journal-title":"Cancer Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/15\/6654\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:53:36Z","timestamp":1785146016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/15\/6654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":46,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ijms27156654"],"URL":"https:\/\/doi.org\/10.3390\/ijms27156654","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]}}}